Each dataset is delivered with precise quantification, internal-standard normalization, and expert interpretation
We will talk about your medical history and your weight loss goals
10.2337/diacare.27.8.1879 61 NikolaidisL
In the UK, from early 2024 to early 2025, approximately 1.6 million adults in England, Wales, and Scotland used GLP-1 class drugs for weight loss, including semaglutide drugs like 'Wegovy' and 'Ozempic', or tirzepatide drugs like 'Mounjaro'
We discuss how these medications work to promote weight loss, the source of their side effects, and the newer compounds soon to overcome some of those side effects, such as muscle loss